Trastuzumab: Symptomatic and asymptomatic cardiotoxicity and sudden cardiac death.

A study examined the cardiotoxicity of trastuzumab, a drug used to treat HER2 positive breast cancer. The study included 117 patients and found that three women experienced cardiac issues during treatment. One woman developed asymptomatic cardiotoxicity, another developed symptomatic cardiotoxicity, and a third woman experienced sudden cardiac death. The study did not provide information on the final outcomes of these adverse reactions or the duration of treatment before the onset of these reactions. [Extracted from the article]